调节载脂蛋白M/S1PR4通路通过自噬和流出机制减轻Alport综合征足细胞脂质过载
该研究在Col4a3敲除小鼠及足细胞中发现APOM/S1P/S1PR4轴失调,表现为APOM降低、S1PR4及S1P升高。给予重组APOM或S1PR4拮抗剂CYM50358可减少蛋白尿、改善肾功能和肾病理,并减轻足细胞脂质蓄积;APOM促进胆固醇流出,而S1PR4拮抗促进脂滴自噬。
要点
- Alport综合征小鼠足细胞存在APOM/S1P/S1PR4轴失调。
- APOM或S1PR4拮抗剂均可改善肾功能和肾病理。
- APOM促胆固醇流出,S1PR4拮抗促脂滴自噬。
核心结论
- 靶向APOM/S1PR4通路可改善Alport综合征小鼠肾功能并减少足细胞脂质蓄积。
研究设计与样本
- 使用Col4a3敲除小鼠及其永生化足细胞作为Alport综合征模型。
- 小鼠和足细胞分别接受重组APOM或S1PR4特异性拮抗剂CYM50358处理。
主要发现
- Col4a3-/-肾小球和足细胞APOM降低、S1PR4表达及S1P水平升高。
- APOM或CYM50358降低蛋白尿、BUN和血肌酐,减轻肾小球硬化、肾小管间质纤维化、足细胞丢失及足突融合。
- 两种处理均减少肾小球和足细胞甘油三酯及胆固醇蓄积。
- S1PR4拮抗上调溶酶体和自噬相关基因,增加LC3-II/LC3-I比值、降低p62,增强自噬流。
- APOM不影响自噬但促进胆固醇流出;APOM敲低或S1PR4过表达足以导致足细胞死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: We identified dysregulation of the apolipoprotein M/sphingosine-1-phosphate/sphingosine-1-phosphate receptor 4 (S1PR4) axis in the glomeruli and podocytes of a mouse model of Alport syndrome. Exogenous apolipoprotein M or antagonism of S1PR4 was sufficient to prevent kidney failure, podocyte injury, and lipid accumulation. Apolipoprotein M reduced lipid accumulation in podocytes via cholesterol efflux, while S1PR4 antagonism promoted autophagy of lipid droplets. BACKGROUND: Renal lipid dysmetabolism contributes to glomerular disease progression, including Alport syndrome. We recently identified alterations in the apolipoprotein M (APOM)/sphingosine-1-phosphate (S1P)/S1P receptor 4 signaling axis in glomeruli from patients with glomerular disease. METHODS: We used Col4a3 knockout mice and immortalized podocytes derived from these mice as a mouse model of Alport syndrome. Mice and podocytes were treated with recombinant APOM or the S1P receptor 4-specific antagonist, CYM50358. RESULTS: Col4a3-/- glomeruli and podocytes exhibited reduced APOM and increased S1P receptor 4 expression and increased sphingosoine-1-phosphate levels, mirroring findings in patients with glomerular disease. Treatment with APOM or CYM50358 reduced albuminuria, BUN, and plasma creatinine and ameliorated glomerulosclerosis, tubulointerstitial fibrosis, podocyte loss, and foot process effacement. Both treatments reduced triglyceride and cholesterol accumulation in glomeruli and podocytes. RNA-seq analysis of Col4a3-/- revealed that S1P receptor 4 antagonism upregulated lysosomal and autophagy-related genes. Western blot analysis confirmed increased LC3-II/LC3-I ratios and decreased p62, indicating enhanced autophagic flux. Treated podocytes showed increased lysosome numbers and colocalization with lipid droplets. By contrast, APOM had no effect on autophagy but promoted cholesterol efflux. Furthermore, knockdown of APOM or overexpression of sphingosine-1-phosphate receptor 4 was sufficient to cause podocyte cell death. CONCLUSIONS: We found that the APOM/S1P axis was dysregulated in Col4a3-/- podocytes. Targeting this pathway through APOM supplementation or S1P receptor 4 antagonism improved kidney function and reduced lipid accumulation by enhancing either cholesterol efflux or autophagy, respectively.
引用
- Tolerico M, Molina J, Insenga A, et al. Modulation of the Apolipoprotein M/S1PR4 Pathway Reduces Podocyte Lipid Overload in Alport Syndrome via Distinct Autophagy and Efflux Mechanisms. J Am Soc Nephrol. 2025. PMID: 41563385. doi:10.1681/ASN.0000000996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。